Puma Biotechnology
PBYI
120 hedge funds and large institutions have $319M invested in Puma Biotechnology in 2021 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 47 increasing their positions, 39 reducing their positions, and 13 closing their positions.
62% more call options, than puts
Call options by funds: $1.13M | Put options by funds: $696K
21% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 39
15% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 13
2% more funds holding
Funds holding: 118 → 120 (+2)
4.84% less ownership
Funds ownership: 90.97% → 86.13% (-4.8%)
10% less capital invested
Capital invested by funds: $356M → $319M (-$36.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$1.83M |
| 2 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$1.72M |
| 3 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$1.52M |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$1.34M |
| 5 |
Prudential Financial
Newark,
New Jersey
|
+$1.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$8.04M |
| 2 |
FAM
Fred Alger Management
New York
|
-$6.49M |
| 3 |
Goldman Sachs
New York
|
-$4.45M |
| 4 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$3.35M |
| 5 |
Nuveen
Charlotte,
North Carolina
|
-$1.35M |
PBYI Hedge Fund Activity: Q2 2021 in Review
120 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Puma Biotechnology (PBYI) for Q2 2021, worth a combined $319M — down 10% from $356M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new PBYI positions and 13 closed out — a net gain of 2 holders — while 47 added to existing stakes and 39 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $1.83M. The largest seller was State Street, cutting an estimated $8.04M.
- 120 institutional investors held Puma Biotechnology (PBYI) as of Q2 2021, up from 118 in Q1 2021.
- Funds reported $319M of Puma Biotechnology stock for Q2 2021, down 10% quarter-over-quarter.
- 15 funds opened new Puma Biotechnology positions in Q2 2021 and 13 closed out, a net change of +2 holders.
- The largest Puma Biotechnology buyer in Q2 2021 was Morgan Stanley, an estimated $1.83M added.
- The largest Puma Biotechnology seller in Q2 2021 was State Street, an estimated $8.04M sold.
Based on aggregated 13F filings for Q2 2021.